An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaPPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerMystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growthInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsTargeting the insulin-like growth factor pathway in hepatocellular carcinomaMonoclonal antibodies for the treatment of cancerUnderstanding cachexia as a cancer metabolism syndromeMechanisms of action of therapeutic antibodies for cancerCombined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysPotentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathwayEvasion mechanisms to Igf1r inhibition in rhabdomyosarcomaAMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathwaysComprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1RIdentification of an inhibitory mechanism of luteolin on the insulin-like growth factor-1 ligand-receptor interaction.Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupReversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancerOverexpression of SATB1 is associated with biologic behavior in human renal cell carcinoma.BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cellsThe type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathwayIGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.IgG expression in human colorectal cancer and its relationship to cancer cell behaviors.Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Animal models of colitis-associated carcinogenesis.Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy.SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer.Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration.Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityChemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo
P2860
Q21129230-C9DD3AEC-BFAA-4BA1-8DCA-EBCCF0A8EE08Q21328702-6917430A-D764-4242-AF27-AB0BB7AA5A6AQ24521364-94705433-957D-4943-827C-A08CE944D418Q24810622-9A811399-2C37-4545-9F79-E6AD433488F6Q27006846-6C1B3FDC-8493-45FA-AE7E-5D7ED7E9B878Q27025966-0B367EA1-EBDA-46B4-A341-B8FE5237D7B5Q28069390-8804D440-9B67-4E5A-B944-447529AB159FQ28385366-0D18BE31-B4F0-42E5-A180-2568FA0672A6Q28484572-1F21E4DD-CC22-443F-9AFC-74CD12BAD41EQ28534009-3E0B7C26-7940-49F4-A204-418F12EEF07CQ30411769-707B017B-9DC7-4A60-B37C-36A4BD3F4F86Q30412634-A429FE14-AB9A-42E0-887B-AA2976AD90C4Q30425784-39FFEE11-535C-41BA-9D7B-86EFC9FD3724Q30573205-3F4866A8-672D-473F-BCD2-02F10303FAA8Q31028788-4C7EA0A2-2EB5-4027-8D3E-E9C0E78F468AQ33398810-F54391D0-22A9-4AD6-90B1-5DDF45BC8D07Q33500359-90E05666-7917-4F72-B354-1B629D19B2B0Q33581021-B62B1D4C-8B9B-4AC5-873D-94A7A45268EAQ33623663-D7CBC9D6-2D58-438F-9BF5-47414B4A31BCQ33642235-BC3D13B5-14C1-4C6C-92A5-558D2443BFC0Q33745823-439EF796-145F-48E1-9330-BA9E8BB3B494Q33890792-8BB3B69E-0193-4F4C-B260-3BE1EE4DEA2DQ33906161-39C56A75-67CC-4E74-A5ED-2167439C018AQ34159954-7B5301BC-A157-4446-B73F-F966FDB81028Q34336988-90F190FF-843F-4309-A131-46141C05DE47Q34442002-DDDC80FA-54C3-4AAA-A8D4-A291976633E1Q34469524-F37487C7-7A37-46A1-A819-F16307C2428FQ34476714-B610570A-FC20-401B-87C7-AC83A8C7EAD9Q34512820-89DFBB5D-3CA0-4B1E-83C3-C61FCCAB66B2Q34539063-2EC1F85C-F248-43D8-A4C6-D4D783AE5C9CQ34550828-7B977862-5916-45D6-8A84-095780F7B177Q34590992-E25AAA9C-E35F-418C-AE40-E9C068255C21Q34673597-5183344F-D0CE-40B5-91EC-23CFDC358A11Q34718036-540D1564-771D-44B7-B907-6DB3800BD444Q35006620-2B326BE2-575E-4782-9EBD-3FAC64FC67E9Q35058305-6AC94B02-74AC-4C83-A43B-D7346A3C883EQ35136127-DEAB6FF1-D997-4D05-B14E-4C7A1BCC969FQ35146077-3F73896B-C609-42A3-A0DB-75D2BD7590E3Q35415181-2C5BEC76-39B7-4A69-8BD5-C02A55BF831DQ35491425-0C10F038-55F0-4B62-80D7-4D3A5AC4F0AE
P2860
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@en
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@nl
type
label
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@en
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@nl
prefLabel
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@en
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@nl
P2093
P1433
P1476
An anti-insulin-like growth fa ...... of cancer cell proliferation.
@en
P2093
Erin K Maloney
Jennifer L McLaughlin
Katherine M Connors
Lisa M Garrett
Nancy E Dagdigian
Rajeeva Singh
Thomas Chittenden
Walter A Blättler
Xiao-Mai Zhou
P304
P407
P577
2003-08-01T00:00:00Z